MeTA country guidance note

Emma Back MeTA Consultant MeTA country guidance note ‘Moving towards medicines data transparency, joint analysis and evidence-based policies to improve access to medicines’ 8 December 2009

Purpose of the guidance note
To provide advice and guidance to MeTA pilot countries – specifically national Secretariats and multi-stakeholder groups – as they take steps towards establishing a process of routine disclosure of key medicines data.
To provide some tools and examples to aid this process, share case studies and lessons from different countries, and identify potential sources of TA.
Broader purpose:
The note will help to ensure standardization of reporting across MeTA countries, which will in turn aid comparison, monitoring and evaluation .

Proposed content
Recap of MeTA pilot phase goals and principles
Purpose of guidance note in this context
Phased approach towards increasing transparency, [accountability,] and evidence-based policy and practice; an ongoing cycle:
Diagnosis
Setting parameters; agreeing reporting format; agreeing process
Data collection / submission; data assessment
Multi-stakeholder discussion of the data
Data use - including for comms, advocacy and policy development
Reporting and monitoring
Using the phased approach in practice
Securing additional support

Questions for you
Does the step-wise approach make sense?
Will the proposed format of the guidance note give you what you need?
What else would you like to see in the note? What do you need most guidance on? TA priorities?
Do you have any case studies or lessons you would like to share through the guidance note?
Any data collection / disclosure / reporting formats?

MeTA country guidance note

by MeTApresents on Jan 15, 2010

Accessibility

Categories

Tags

Upload Details

Usage Rights

1 Embed 2

Statistics

MeTA country guidance note — Presentation Transcript